Literature DB >> 8102095

Glucagon-like peptide-1-(7-36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line.

L Gros1, B Thorens, D Bataille, A Kervran.   

Abstract

Glucagon-like peptide-1(7-36)amide (tGLP-1), oxyntomodulin (OXM), and glucagon are posttranslational end products of the glucagon gene expressed in intestinal L-cells. In vivo, these peptides are potent inhibitors of gastric acid secretion via several pathways, including stimulation of somatostatin release. We have examined the receptors through which these peptides stimulate somatostatin secretion using the somatostatin-secreting cell line RIN T3. tGLP-1, OXM, and glucagon stimulated somatostatin release and cAMP accumulation in RIN T3 cells to similar maximum levels, with ED50 values close to 0.2, 2, and 50 nM and 0.02, 0.3, and 8 nM, respectively. Binding of [125I]tGLP-1, [125I]OXM, and [125I]glucagon to RIN T3 plasma membranes was inhibited by the three peptides, with relative potencies as follows: tGLP-1 > OXM > glucagon. Whatever the tracer used, the IC50 for tGLP-1 was close to 0.15 nM and was shifted rightward for OXM and glucagon by about 1 and 2-3 orders of magnitude, respectively. Scatchard analyses for the three peptides were compatible with a single class of receptor sites displaying a similar maximal binding close to 2 pmol/mg protein. In the hamster lung fibroblast cell line CCL39 transfected with the receptor for tGLP-1, binding of [125I]tGLP-1 was inhibited by tGLP-1, OXM, and glucagon, with relative potencies close to those obtained with RIN T3 membranes. Chemical cross-linking of [125I]tGLP-1, [125I]OXM, and [125I]glucagon revealed a single band at 63,000 mol wt, the intensity of which was dose-dependently reduced by all three peptides. These data suggest that in the somatostatin-secreting cell line RIN T3, OXM and glucagon stimulate somatostatin release through a tGLP-1-preferring receptor. This suggests that some biological effects, previously described for these peptides, might be due to their interaction with this receptor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8102095     DOI: 10.1210/endo.133.2.8102095

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  20 in total

1.  Rise of oxyntomodulin in response to oral glucose after gastric bypass surgery in patients with type 2 diabetes.

Authors:  Blandine Laferrère; Nicholas Swerdlow; Baani Bawa; Sara Arias; Mousumi Bose; Blanca Oliván; Julio Teixeira; James McGinty; Kristina I Rother
Journal:  J Clin Endocrinol Metab       Date:  2010-05-25       Impact factor: 5.958

Review 2.  Gut hormones ghrelin, PYY, and GLP-1 in the regulation of energy balance [corrected] and metabolism.

Authors:  Diego Perez-Tilve; Ruben Nogueiras; Federico Mallo; Stephen C Benoit; Matthias Tschoep
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

3.  Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.

Authors:  J Schirra; K Sturm; P Leicht; R Arnold; B Göke; M Katschinski
Journal:  J Clin Invest       Date:  1998-04-01       Impact factor: 14.808

Review 4.  Obesity: Current and potential pharmacotherapeutics and targets.

Authors:  Vidya Narayanaswami; Linda P Dwoskin
Journal:  Pharmacol Ther       Date:  2016-10-20       Impact factor: 12.310

Review 5.  Therapy for obesity based on gastrointestinal hormones.

Authors:  Jonatan I Bagger; Mikkel Christensen; Filip K Knop; Tina Vilsbøll
Journal:  Rev Diabet Stud       Date:  2011-11-10

Review 6.  The Gut as an Endocrine Organ: Role in the Regulation of Food Intake and Body Weight.

Authors:  Audrey Melvin; Carel W le Roux; Neil G Docherty
Journal:  Curr Atheroscler Rep       Date:  2016-08       Impact factor: 5.113

7.  Glucagon-like peptide-1 stimulates luteinizing hormone-releasing hormone secretion in a rodent hypothalamic neuronal cell line.

Authors:  S A Beak; M M Heath; C J Small; D G Morgan; M A Ghatei; A D Taylor; J C Buckingham; S R Bloom; D M Smith
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

8.  Delta cell secretory responses to insulin secretagogues are not mediated indirectly by insulin.

Authors:  A C Hauge-Evans; R L Anderson; S J Persaud; P M Jones
Journal:  Diabetologia       Date:  2012-04-13       Impact factor: 10.122

9.  Can Bayliss and Starling gut hormones cure a worldwide pandemic?

Authors:  R V Scott; T M Tan; S R Bloom
Journal:  J Physiol       Date:  2014-09-12       Impact factor: 5.182

10.  Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.

Authors:  Alessandro Pocai; Paul E Carrington; Jennifer R Adams; Michael Wright; George Eiermann; Lan Zhu; Xiaobing Du; Aleksandr Petrov; Michael E Lassman; Guoqiang Jiang; Franklin Liu; Corey Miller; Laurie M Tota; Gaochao Zhou; Xiaoping Zhang; Michael M Sountis; Alessia Santoprete; Elena Capito'; Gary G Chicchi; Nancy Thornberry; Elisabetta Bianchi; Antonello Pessi; Donald J Marsh; Ranabir SinhaRoy
Journal:  Diabetes       Date:  2009-07-14       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.